Results 81 to 90 of about 34,241 (258)

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source

Targeting KDM3B Elicits Anti‐tumor Immunity by Alleviating SHP1–mediated STING Suppression in Triple–Negative Breast Cancer

Advanced Science, EarlyView.
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang, Wenhao Li, Yifei Wang, Ning Zhang, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Qifeng Yang   +8 more
wiley   +1 more source

CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling

BMC Immunology, 2021
Background Tumor-associated dendritic cells (TADCs) can interact with tumor cells to suppress anti-tumor T cell immunity. However, there is no information on whether and how TADCs can modulate programmed death-ligand 1 (PD-L1) expression by cancer cells.
Weigang Xiu, Jingjing Luo
doaj   +1 more source

CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism

Blood, 2005
AbstractRecently, inhibitory cytokine pathways for leukocyte chemoattraction and activation have been identified, but there is little insight into the operational mechanisms except for models that rely on simple receptor antagonism. We have previously identified the existence of a murine eosinophil inhibitory pathway mediated by the CXC chemokine ...
Patricia C, Fulkerson, Hongyan, Zhu, David A, Williams, Nives, Zimmermann, Marc E, Rothenberg   +4 more
openaire   +3 more sources

Data on the expression of CXCR3 ligands and pro-inflammatory cytokines in macrophages and CD4+ T cells after stimuli of CXCR3 ligands

Data in Brief, 2018
C-X-C motif chemokine receptor 3 (CXCR3) is a G protein-coupled receptor for three ligands which are C-X-C motif chemokine 9 (CXCL9), CXCL10, and CXCL11 [1]. Previously we have reported that CXCL10 promotes pro-inflammatory cytokine expression, and forms
Bongjun Kim, Jong-Ho Lee, Won Jong Jin, Hong-Hee Kim, Hyunil Ha, Zang Hee Lee   +5 more
doaj   +1 more source

Expression of macrophage markers in cryoglobulinemic glomerulonephritis - a possible role of CXCL9

Advances in Medical Sciences, 2013
Cryoglobulinemic glomerulonephritis (CGGN) is a type of membranoproliferative glomerulonephritis (MPGN) that develops in patients with systemic cryoglobulinemia. To date the exact pathogenesis of CGGN remains unclear. It has been suggested that macrophages may be significant contributors to the glomerular injury in this disease. In our study we attempt
Kowalewska, J., Okoń, Krzysztof, Szynaka, B., Naumnik, B.   +3 more
openaire   +3 more sources

The chemokine fragment CXCL9(74–103) diminishes neutrophil recruitment and joint inflammation in antigen-induced arthritis

, 2018
This study investigates if treatment with a peptide corresponding to the 30 C-terminal amino acids of CXCL9, CXCL9(74–103), ameliorates joint inflammation in a murine model of antigen-induced arthritis (AIA).
Daiane Boff, Gustavo B Menezes, Flavio A Amaral, Soraia Macari, Tarcilia A Silva, Rik Janssens, Vincent Vanheule, Paul Proost, Helena Crijns   +8 more
core   +1 more source

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Advanced Science, EarlyView.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen, Xiaoyun Luo, Huixin Gao, Yujing Ke, Yu Zhan, Xiaoting Xu, Xiaoxiao Xiong, Fengjiao Wei, Si Yang, Zhonghua Liu, Bolan Yu, Zhaofeng Huang, Yingjie Bian   +12 more
wiley   +1 more source

698 Validation of CXCL9 as a biomarker in morphea [PDF]

Journal of Investigative Dermatology, 2021
G. Barber, J. O'Brien, H. Chen, H. Jacobe   +3 more
openaire   +1 more source

Fibronectin and fibrinogen binding to CXCL9, CXCL10 and CXCL11.

, 2013
CXCL9, CXCL10 and CXCL11 binding to FN (A) and Fg (B) was determined by indirect ELISA and calibrated to PDGF-BB binding to FN as a strongly binding reference (Abs 450nm = 0.59 AU) and Fg (Abs 450 nm=0.79 AU), respectively. FN and Fg binding to BSA were
Priscilla S. Briquez (477140), Mikaël M. Martino (445359), Marco Pisano (477139), Jeffrey A. Hubbell (118232), Federico Tortelli (43158)   +4 more
core   +1 more source